Dermatology is no longer driven only by new drugs and treatments. Innovation increasingly depends on how effectively companies generate clinical evidence, manage scientific data, support medical affairs, educate healthcare professionals, and translate complex research into useful information.

This need is growing because skin diseases affect a significant number of people. The latest U.S. government data show that 7.7% of adults had diagnosed eczema in 2024, including 9.5% of women and 5.7% of men. Adults aged 18 – 44 had the highest reported prevalence at 9.1%.

At the same time, skin cancer remains the most common form of cancer in the United States. CDC data indicate that approximately 6.1 million adults are treated for basal cell and squamous cell carcinomas each year, with estimated treatment costs of USD 8.9 billion annually.

Against this backdrop, companies that can improve access to reliable dermatology science and medical information are becoming increasingly important.

The Companies Worth Watching

Based on insights from Towards Healthcare, Innovaderm Research, LEO Pharma, Galderma, and Almirall stand out because they represent different approaches to dermatology research, evidence generation, medical education, and scientific communication.

Innovaderm Research: Specialized Clinical Evidence

Innovaderm Research stands out for its specialized focus on dermatology clinical research.

For pharmaceutical and biotechnology companies, dermatology studies can involve complex disease scoring, visual assessments, patient-reported outcomes, imaging, and long-term follow-up. A specialist research partner can therefore provide value beyond general clinical-trial operations.

The innovation here is dermatology-specific scientific expertise. Instead of using a broad, one-size-fits-all clinical research model, specialized companies can focus on generating evidence around the unique requirements of skin diseases.

Expert Perspective by Payal Rabde – uncovering key trends and opportunities across the healthcare industry.

LEO Pharma: Research Combined With Scientific Education

LEO Pharma has a strong presence in medical dermatology and represents another important approach: connecting therapeutic development with scientific resources and healthcare-professional education.

The need for this is substantial. The U.S. FDA’s dermatology-focused drug division oversees therapies and biologics across conditions including acne, atopic dermatitis, psoriasis, rosacea, actinic keratosis, and certain skin cancers. As therapies become more targeted, healthcare professionals need increasingly specialized scientific information.

This makes evidence communication just as important as evidence generation.

Galderma: Medical Affairs at Scale

Galderma is notable for its scale across dermatology and its ability to support scientific engagement and medical information across professional audiences.

Innovation in this area is not simply about publishing more research. Healthcare professionals increasingly need information that answers practical questions:

• Which patients were included in a clinical trial?
• How strong is the evidence?
• What were the treatment outcomes?
• Are there demographic differences in benefits or adverse effects?
• How does new evidence apply to clinical practice?

The FDA’s Drug Trials Snapshots program reflects the growing importance of making clinical-trial information more transparent. It provides information on participants in key trials supporting drug approvals, including demographic characteristics and potential differences in benefits and side effects.

Almirall: Making Complex Dermatology Evidence More Accessible

Almirall is another company highlighted for its dermatology specialization and scientific communication capabilities.

The challenge in medical information is clear: more data does not automatically mean better decisions.

Healthcare professionals need evidence that is:

Scientifically credible → Clinically relevant → Easy to access → Updated → Applicable to real-world decisions

Companies that can bridge the gap between scientific complexity and practical medical understanding could become increasingly valuable partners across dermatology.

The Government Numbers Show Why Innovation Is Needed

7.7% of U.S. Adults Had Diagnosed Eczema

According to the CDC’s National Health Interview Survey, 7.7% of U.S. adults had diagnosed eczema in 2024. The prevalence was higher among women at 9.5%, compared with 5.7% among men.

There were also important differences by age:

• 18–44 years: 9.1%
• 45–64 years: 6.8%
• 65–74 years: 6.3%
• 75 years and older: 5.6%

The data highlight the large population that may require dermatology-related information, diagnosis, treatment, and ongoing disease management.

Nearly One-Third of Adults Reported a Selected Allergic Condition

The CDC also reported that 31.7% of U.S. adults had at least one of three diagnosed conditions in 2024: seasonal allergy, eczema, or food allergy.

Breaking down the data:

• 25.2% had a seasonal allergy
• 7.7% had eczema
• 6.7% had a food allergy

While these conditions are not all dermatology diseases, they demonstrate the scale of immune- and allergy-related health needs that can overlap with conditions such as atopic dermatitis and other inflammatory skin disorders.

Skin Cancer Adds Another Major Evidence Challenge

Dermatology scientific information is also essential in oncology.

According to the U.S. National Cancer Institute’s SEER program, an estimated 112,000 new melanoma cases will be diagnosed in the United States in 2026, representing 5.3% of all new cancer cases.

The agency also estimates 8,510 deaths from melanoma in 2026. However, the five-year relative survival rate was 94.7% for cases diagnosed during 2016–2022.

These numbers demonstrate why rapid access to evolving clinical evidence remains important.

For scientific-information teams, melanoma alone can involve a rapidly changing evidence base around:

Diagnosis → Staging → Molecular characteristics → Surgery → Immunotherapy → Targeted therapy → Follow-up

The ability to organize and communicate this information effectively is becoming a major capability.

Skin Cancer Creates an USD 8.9 Billion Annual Treatment Burden

CDC data provide another important perspective.

Approximately 6.1 million U.S. adults are treated annually for basal cell and squamous cell carcinomas, with estimated annual treatment costs of around USD 8.9 billion.

This is a powerful statistic because it shows that innovation in dermatology is not limited to rare diseases or premium therapies.

There is a massive need for better information across prevention, diagnosis, treatment, follow-up, and healthcare decision-making.

Dermatology Is Also Entering a More Digital Evidence Era

One of the biggest shifts is the use of digital technologies in research and evidence generation.

The FDA’s ISTAND program specifically identifies patient-performed digital photography in dermatology trials as an example of a novel approach that may be considered under the program. The FDA also highlights AI-based algorithms and other digital health technologies as potential tools for evaluating patients, developing endpoints, and informing study design.

However, innovation in dermatology does not mean technology alone.

The real value comes from connecting:

Clinical research → Patient data → Digital evidence → Scientific analysis → Medical information → Healthcare professionals

This is where companies with strong research and medical-information capabilities could differentiate themselves.

FDA Data Shows a Growing Innovation Pipeline

As of January 1, 2026, the FDA reported:

• 63 drug development tool projects in development
• 53 Letters of Intent accepted
• 10 Qualification Plans accepted
• 3 newly qualified drug development tools in the previous 12 months
• 11 total qualified drug development tools to date

The FDA’s ISTAND program alone had 16 projects in development, with 14 Letters of Intent and 2 Qualification Plans accepted.

These figures are not dermatology-specific, but they show the broader direction of scientific and medical innovation: pharmaceutical research is increasingly incorporating new evidence-generation tools, digital technologies, and novel approaches.

Dermatology-focused companies that can successfully adopt these capabilities may gain an important advantage.

Galderma vs. LEO Pharma: Different Innovation Models

Both companies are important, but their strengths differ.

Galderma has broad dermatology expertise and significant capabilities across scientific engagement and medical affairs.

LEO Pharma has a strong focus on medical dermatology and connects therapeutic development with scientific resources and education.

The choice between these approaches depends on what healthcare professionals or life-sciences companies need.

For large-scale scientific communication and engagement, Galderma’s broad ecosystem is particularly relevant.

For medical dermatology-focused evidence and therapeutic expertise, LEO Pharma represents a strong specialized approach.

Innovaderm Research vs. Almirall: Research Infrastructure vs. Evidence Communication

These companies also represent different parts of the scientific-information value chain.

Innovaderm Research is particularly relevant to the generation and management of dermatology clinical evidence.

Almirall is strongly positioned around medical dermatology, scientific expertise, and communication.

In simple terms:

Innovaderm Research helps generate specialized evidence → Almirall helps translate scientific expertise into meaningful medical knowledge.

Both functions are important because scientific information is only valuable when there is reliable evidence behind it and when the evidence can be effectively communicated.

What Do Pharmaceutical and Healthcare Buyers Actually Want?

For buyers evaluating dermatology scientific and medical-information partners, the biggest requirements are becoming clearer.

Dermatology Expertise

Generic medical knowledge may not be enough. Buyers increasingly value partners that understand dermatology-specific diseases, endpoints, patient populations, and clinical workflows.

Reliable Data

The quality of scientific evidence remains fundamental. Companies need accurate and traceable information.

Faster Access to Evidence

Scientific teams and healthcare professionals cannot always wait for information to move through fragmented systems.

Clinical Relevance

More than data, users want answers to practical questions that can support research and clinical decisions.

Digital Evidence Capabilities

FDA recognition of approaches such as digital photography in dermatology trials shows that digital evidence-generation methods are becoming increasingly relevant.

Transparent Clinical Information

FDA Drug Trials Snapshots demonstrate the increasing importance of transparency around who participated in clinical trials and how treatments performed across demographic groups.

The Role of Towards Healthcare

According to insights from Towards Healthcare, innovation in dermatology scientific and medical information is being shaped by companies that combine specialized clinical research, therapeutic expertise, medical affairs, scientific education, and advanced approaches to managing complex medical information.

The companies highlighted Innovaderm Research, LEO Pharma, Galderma, and Almirall—are important because they do not all solve the same problem.

Their capabilities cover different parts of the ecosystem:

Innovaderm Research → Dermatology clinical research and evidence generation

LEO Pharma → Medical dermatology research and scientific education

Galderma → Medical affairs and scientific engagement

Almirall → Medical dermatology expertise and scientific communication

About Us

Pharma Geek is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.

You can place an order or ask any questions, please feel free to contact us at [email protected]

Europe Region – +44 778 256 0738

North America Region – +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium